Deaths caused by hepatitis C has declined by 35 per cent in England between 2015 and 2020, latest data from the UK Health Security Agency (UKHSA) revealed.
It showed that estimated prevalence of chronic hepatitis C in England has continued to fall to around 81,000 in 2020 from 129,000 in 2015, showing a considerable progress has been made towards eliminating the virus as a public health problem by 2030 in England.
Commenting on the data release, health and social care secretary Sajid Javid, said: "It is fantastic to see the significant progress that has been made in eliminating hepatitis C in England. Deaths and prevalence of the virus have fallen consistently thanks to improvements in diagnosis, access to treatments and the hard work of the NHS.
"This is another example of the UK being at the forefront of tackling serious diseases. We are on track to eliminate this virus by 2030 and I urge anyone who may be at risk to get tested as soon as possible."
Acknowledging the ongoing challenges in delivering the required IT systems for the scheduled launch of the Pharmacy First service on January 31, NHS England
reported progress in fulfilling 'many' commitments outlined in its plan to enhance primary care access during a board meeting on Thursday.
However, it noted that the digital infrastructure supporting Pharmacy First, included in the £645 million fresh funding for community pharmacy, will require additional time for implementation.
"Delivery remains challenging due to changes needed in digital infrastructure, and we are working with suppliers to support January implementation," NHSE said.
"A public campaign is planned for 2024."
The Pharmacy First service allows pharmacists to supply prescription-only medicines for seven common health conditions (sinusitis, sore throat, earache, infected
insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women), eliminating the need for a GP visit.
Meanwhile, NHSE is leveraging the widespread accessibility of pharmacies by expanding blood pressure monitoring and introducing direct prescribing of clinically
safe oral contraceptives-an initiative that has been well-received.
The Association of the British Pharmaceutical Industry (ABPI) has supported the Department of Health and Social Care's recommendation to 'aggressively expedite and roll out new medicines' that have gone through trials.
The ABPI welcomes government report on cancer services in England and the opportunity it provides to refocus how the pharmaceutical industry, NHS and government can improve the lives of cancer patients.
David Watson, executive director, Patient Access at the ABPI, said: "Despite progress, UK patients still have much worse five-year survival rates for many cancers than those in similar nations. Early diagnosis and fast and equal access to the latest treatments for all patients is key to reversing poor trends in NHS cancer care.
"We are pleased that the report reflects concerns about variable access to cancer medicines. We support the Committee's recommendations to 'aggressively expedite
and roll out new medicines' that have gone through trials and to ensure regulatory innovation results in swift uptake in the UK.
The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments
to pharmacy services in England on Wednesday (26 April).
"They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments
across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said
DHSC.
Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never
been more important.
"The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets.
"In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers
of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce."
National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five
standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.
The Royal Pharmaceutical Society (RPS) in England has published a review of its 10-year Vision for Pharmacy Professional Practice that was launched in
December 2022 in collaboration with The King's Fund.
The 'one year on' vision report highlighted key milestones achieved in the first 12 months since its publication as well as opportunities for further progress.
It identified the publication of the NHS Long Term Workforce Plan, which recognises the significant role that pharmacists play in healthcare and commits to growing
and expanding the pharmacy workforce, as one of the positive policy developments made since the launch of the vision.
The development of a Vision for Community Pharmacy by Community Pharmacy England, the Nuffield Trust and The King's Fund; work on digital integration to enable
community pharmacists to update a clinical record; the launch of Pharmacy First scheme; and the publication of the public consultation of pharmacy supervision
were other key milestones mentioned in the report.
The NHS's latest report on ambulance services in England for March 2024 reveals significant progress in response times for emergency calls across all
categories compared to recent months.
The Ambulance Quality Indicators (AQI) Statistical Note, released in April, underscores both improvements and persistent challenges within the sector.
Recent figures obtained from the Liberal Democratic party suggest ongoing struggles with response times, particularly for category two patients, which may
include individuals experiencing strokes or heart attacks requiring a response within 18 minutes.
Similarly, in November last year, ambulance waits for category 2 calls surged to their highest level since December 2022, reaching 93 minutes, after dropping
to 32 minutes in January 2023 according to the British Heart Foundation.
However, according to the latest statistical figures obtained from AQI, March 2024 witnessed the shortest average response times for all four categories of
emergency calls since August 2023.
The Health Select Committee Expert Panel has concluded in its report published on Tuesday (25 July) that the funding aspect in the community pharmacy sector
'requires improvement' based on the evidence received.
The Expert Panel reviewed nine Government commitments, seven of which were from the Community Pharmacy Contractual Framework.
It was found that available funding was not sufficient to keep pharmacies open, struggling financially with increased demand for dispensing, workforce pressures
and rising costs due to inflation. One of the other commitments requiring improvement covered a scheme intended to protect access to local physical NHS pharmaceutical
services in areas where there were fewer pharmacies.
Professor Dame Jane Dacre, Chair of the Expert Panel, said: "Pharmacy plays a key role in the delivery of care so it's disappointing that progress overall to
deliver on the Government's commitments was rated as 'requires improvement'.